Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | VCP | P55072 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | CCND2 | P30279 | 1/20 | 0.30 |
| ▸ | CCND3 | P30281 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229294 | 0.85 | VCP (0.46) | ADORA1ADORA3ADORA2AVCPSYK | |
| SCHEMBL3233990 | 0.85 | VCP (0.44) | ADORA1ADORA3ADORA2AVCPSYK | |
| SCHEMBL3228883 | 0.85 | ADORA1 (0.40) | ADORA1ADORA3ADORA2AGPR183VCP | |
| SCHEMBL3229963 | 0.84 | ADORA1 (0.38) | ADORA1ADORA3ADORA2AGPR183VCP | |
| SCHEMBL3235616 | 0.81 | SYK (0.40) | ADORA1ADORA3VCPSYK | |
| SCHEMBL3422029 | 0.81 | IDH2 (0.38) | ADORA1VCPSYK | |
| SCHEMBL3266663 | 0.79 | IDH2 (0.38) | ADORA1VCPSYK | |
| SCHEMBL3261709 | 0.78 | ADORA3 (0.46) | ADORA1ADORA3ADORA2AGPR183VCP | |
| SCHEMBL3233801 | 0.77 | MAPT (0.40) | ADORA1VCPGBA1SYK | |
| SCHEMBL3419816 | 0.77 | IDH2 (0.40) | ADORA1VCPSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | claimed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | ADORA1 2916/4885ADORA3 3583/4885ADORA2A 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.